but evergreening will save us ! a recent report has indicated that sales of atypical antipsychotics may be enjoying their apex now , but not for long decision resources , one of the world 's leading research and advisory firms for pharmaceutical and healthcare issues , finds that generic competition will end the robust growth of the schizophrenia drug market atypical antipsychotic sales will decrease from billion in to billion in all five currently on patent agents janssen 's risperdal and risperdal consta risperidone , eli lilly 's zyprexa olanzapine , astrazeneca 's seroquel quetiapine , pfizer 's geodon zeldox ziprasidone , and bristol myers squibb otsuka 's abilify aripiprazole will lose patent protection in the united states by risperidone is the first to face generic competition , in in the united states , in europe , and in japan generic competition 's effect on the risperdal brand will be most profound in the u s market we forecast that of patients will be on a generic form of the molecule in , and the price of the generic will be of the brand that year , said nitasha manchanda , ph d , analyst at decision resources risperdal consta , the depot form of the drug , remains on patent until however , its use will be too low to preserve franchise sales in , approximately of drug treated patients will be treated with a generic antipsychotic of course , there is hope for the manufacturers evergreening the term , as many of my readers know , loosely means to extend the patent life of a drug as long as possible antipsychotic drug manufacturers can follow standard practices , including the following getting their products approved for new indications after all , atypical antipsychotics are now being rebranded as broad spectrum psychotropic agents not that it matters that the atypicals show no substantial improvement in efficacy or safety over existing products in the areas in which they will be marketed increase marketing even when generic competition arrives , a marketing blitz can buy time release in extended release format this is becoming a time honored classic reformulate the existing product molecule just enough to remarket it as a brand new product it doesn t work all the time as seems to be the case with effexor , but it sometimes works wonders celexa lexapro or , better yet , prilosec nexium from a merck medco report food and drug administration fda approvals of the last decade highlight the prevalence of evergreening strategies during the s , the fda approved a total of new drug applications were for drugs containing existing active ingredients nearly half were new formulations or new fixed combinations of existing drugs an additional were existing products marketed by a new manufacturer drag patent issues out in court as long as possible to prevent release of generic forms of medication pay generic drug manufacturers to not create generic versions of your drug none of the above is likely to actually yield substantial benefit for patients one could argue that extended release pills enhance compliance , which then enhances outcomes , but i m not familiar with any data to support such an assertion an interesting brief article about some of the above tactics , go here or just tool around the pharmagossip site for a plentitude of examples